Tripp is (I think) the first RCT of oncosil.
RCT level evidence is what’s required for public reimbursement.
It could be enough for public reimbursement in Germany France and maybe even NICE in the UK. Maybe even TGA here. It will depend on whether they accept tge outcomes.
The USA FDA imo will be something for whoever takes OSL over. Maybe in the past they thought they could keep EU and sell US rights but that’s a pipe dream now. Now they will need to sell the whole thing.
Tripp is (I think) the first RCT of oncosil. RCT level evidence...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.020(2.00%) |
Mkt cap ! $14.50M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | 99.5¢ | $44.55K | 44.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 192 | $1.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 6234 | 1 |
View Market Depth
| Last trade - 15.48pm 25/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |